Protein Scaffolds, Antisense Oligonucleotide

Aro Biotherapeutics is at the forefront of developing a new class of receptor-targeted genetic medicines through its proprietary Centyrin platform. Centyrins are engineered proteins derived from the human protein Tenascin C, designed to achieve exceptional stability and biophysical properties, which are crucial for effective therapeutic delivery within cells. The company focuses on creating Centyrin-based drug conjugates, particularly Centyrin-siRNA conjugates, that can selectively modulate gene targets in disease tissues. This targeted approach aims to enhance the efficacy and safety of treatments for various diseases, including orphan genetic and immune-mediated conditions. Aro's strategy includes both a wholly-owned pipeline and collaborations with industry partners to expand the application of Centyrins across different therapeutic areas.

The Centyrin platform offers several advantages over traditional antibody-based therapies, including smaller size for better tissue penetration, lower immunogenicity, and the ability to customize drug exposure profiles. Aro's innovative approach allows for the rapid identification of Centyrin variants that bind with high specificity to cell surface receptors, facilitating the targeted delivery of oligonucleotides and other drug payloads. This technology is particularly promising for conditions like Pompe Disease, where Aro is developing ABX1100, a first-in-class Centyrin-siRNA conjugate aimed at reducing glycogen levels in muscle tissue. The preclinical success of this approach demonstrates the potential for durable and specific gene modulation, paving the way for new treatment options that address significant unmet medical needs.

United States

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.

Aro Biotherapeutics

Company Details